News articles about Rubius Therapeutics (NASDAQ:RUBY) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rubius Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the company an impact score of 48.3006856883898 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of research analysts recently weighed in on RUBY shares. Jefferies Financial Group started coverage on Rubius Therapeutics in a report on Monday, August 13th. They set a “buy” rating and a $40.00 target price on the stock. Leerink Swann started coverage on Rubius Therapeutics in a report on Monday, August 13th. They set an “outperform” rating on the stock. Morgan Stanley started coverage on Rubius Therapeutics in a report on Monday, August 13th. They set an “overweight” rating and a $37.00 target price on the stock. Finally, JPMorgan Chase & Co. started coverage on Rubius Therapeutics in a report on Monday, August 13th. They set an “overweight” rating on the stock.

Shares of RUBY stock traded up $0.39 during trading on Wednesday, reaching $21.01. 20,474 shares of the company’s stock were exchanged, compared to its average volume of 122,415. Rubius Therapeutics has a twelve month low of $19.78 and a twelve month high of $33.01.

Rubius Therapeutics (NASDAQ:RUBY) last posted its earnings results on Friday, August 31st. The company reported ($3.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($2.73). During the same period last year, the business earned ($1.25) earnings per share. equities analysts forecast that Rubius Therapeutics will post -1.69 EPS for the current year.

In other Rubius Therapeutics news, Director Francis M. Cuss bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, July 20th. The shares were acquired at an average cost of $23.00 per share, with a total value of $230,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Rubius Therapeutics Company Profile

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.

See Also: Trading Strategy Examples and Plans

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.